GB0501352D0 - Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope - Google Patents

Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope

Info

Publication number
GB0501352D0
GB0501352D0 GBGB0501352.9A GB0501352A GB0501352D0 GB 0501352 D0 GB0501352 D0 GB 0501352D0 GB 0501352 A GB0501352 A GB 0501352A GB 0501352 D0 GB0501352 D0 GB 0501352D0
Authority
GB
United Kingdom
Prior art keywords
treatment
combination
infections caused
membrane fusion
fusion inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0501352.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MNL Pharma Ltd
Original Assignee
SLINGSBY JASON H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SLINGSBY JASON H filed Critical SLINGSBY JASON H
Priority to GBGB0501352.9A priority Critical patent/GB0501352D0/en
Publication of GB0501352D0 publication Critical patent/GB0501352D0/en
Priority to PCT/GB2006/000209 priority patent/WO2006077427A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0501352.9A 2005-01-21 2005-01-21 Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope Ceased GB0501352D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0501352.9A GB0501352D0 (en) 2005-01-21 2005-01-21 Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope
PCT/GB2006/000209 WO2006077427A2 (en) 2005-01-21 2006-01-20 Antiviral drug combinations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0501352.9A GB0501352D0 (en) 2005-01-21 2005-01-21 Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope

Publications (1)

Publication Number Publication Date
GB0501352D0 true GB0501352D0 (en) 2005-03-02

Family

ID=34259511

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0501352.9A Ceased GB0501352D0 (en) 2005-01-21 2005-01-21 Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope

Country Status (2)

Country Link
GB (1) GB0501352D0 (en)
WO (1) WO2006077427A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614098D0 (en) * 2006-07-15 2006-08-23 Mnl Pharma Ltd Immune response variegation with imino sugars
WO2010096764A1 (en) 2009-02-23 2010-08-26 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
CN102625660B (en) * 2009-02-24 2015-03-11 联合治疗公司 Iminosugars and methods of treating arenaviral infections
ES2524361T3 (en) 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares for use in the treatment of bunyavirus and togavirus diseases
KR20120081990A (en) * 2009-09-04 2012-07-20 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 Iminosugars and methods of treating filoviral diseases
BR112012004676A2 (en) * 2009-09-04 2019-09-24 United Therapeutics Corp method of treating orotomixoviral infections.
CN102625801B (en) * 2009-09-04 2015-09-09 联合治疗公司 The method for the treatment of poxvirus infection
CN102659787B (en) * 2011-03-29 2015-04-01 中国科学院化学研究所 Fluoro polyhydroxy pyrrole pyrrolizidine, and preparation method and application thereof
AU2013203400B2 (en) * 2013-03-15 2016-01-21 National University Of Singapore Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
WO2014179438A2 (en) * 2013-05-02 2014-11-06 The Chancellor, Masters And Scholars Of The University Of Oxford Glycolipid inhibition using iminosugars
CN103435619B (en) * 2013-09-04 2015-08-05 中国科学院化学研究所 A kind of Pochonicine analogue or its pharmacy acceptable salt and application thereof
US20220257604A1 (en) * 2019-03-08 2022-08-18 University Of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides
AU2020274430A1 (en) * 2019-05-10 2021-11-25 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
EP4031172A4 (en) * 2019-09-16 2024-02-21 Chen, Dalu Methods of blocking asfv infection through interruption of cellular receptors
WO2021168483A2 (en) * 2020-02-21 2021-08-26 Florida State University Research Foundation, Inc. Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
IT202000008917A1 (en) * 2020-04-24 2021-10-24 Biovalley Invest Partner S R L ANTIVIRAL COMPOSITIONS
CN112294806B (en) * 2020-10-26 2022-11-29 西北农林科技大学 Application of 1-formyl-beta-carboline derivative in preparation of anti-newcastle disease virus drugs
CN115137736A (en) * 2022-02-17 2022-10-04 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Medicine for resisting African swine fever virus and screening method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA883925B (en) * 1987-06-08 1989-02-22 Merrell Dow Pharma Inhibitors of glycoprotein processing having anti-retroviral activity
CA2224008C (en) * 1995-06-07 2009-08-18 Trimeris, Inc. The treatment of hiv and other viral infections using combinatorial therapy
GB0301554D0 (en) * 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions

Also Published As

Publication number Publication date
WO2006077427A3 (en) 2006-09-14
WO2006077427A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
GB0501352D0 (en) Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope
PL2356914T3 (en) Composition for improving membrane composition and functioning of cells
IL185441A0 (en) Cellulose solutions in ionic liquids
IL189236A0 (en) Membrane sterilization
GB2441939B (en) Surgical membrane
GB2426812B (en) Improvements in or relating to contact lenses
GB2464646B (en) Isolator
PL3663072T3 (en) Biaxially oriented microporous membrane
WO2007021672A3 (en) Vaccination against dengue virus infection
EP1950283A4 (en) Aqueous solution for cell preservation
GB0511908D0 (en) Improvements in or relating to drive systems
PT1905453E (en) Preservative composition for ophthalmic use
HK1126128A1 (en) Medicament for use in connection with cartilage impairment
GB2430188B (en) Improvements in or relating to valves
DE602006013255D1 (en) Composition for external use containing an ionic liquid
GB0615287D0 (en) Integral membrane protein
IL206337A0 (en) Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
GB0401509D0 (en) Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses
GB0621824D0 (en) Zeolite l crystals with cells or viruses
ZA200708652B (en) Purification of proteins with cationic surfactant
FI20050081A0 (en) Membrane structure and method for reducing glare
GB0423505D0 (en) Improvements in or relating to pipework assemblies
GB2430692B (en) Improvements in or relating to frames
AU2006906190A0 (en) Frame for use in the oaking of an alcoholic beverage
GB0505583D0 (en) Improvements in or relating to optical systems

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: MNL PHARMA LIMITED

Free format text: FORMER APPLICANT(S): SLINGSBY, JASON H

AT Applications terminated before publication under section 16(1)